Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
NCT00321308
Last updated date
ABOUT THIS STUDY
To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed
for the treatment of patients with locally advanced or metastatic NSCLC who have failed one
prior chemotherapy regimen
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Non-Small Cell Lung Carcinoma
Sex
Females and Males
Age
18 + years
Inclusion Criteria
Show details
- Locally advanced or metastatic NSCLC
- Measurable disease
- ECOG PS 0 or 1
Exclusion Criteria
Show details
- Known CNS metastasis
- Pre-existing autoimmune or antibody mediated disease
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Non-Small Cell Lung CarcinomaA Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
NCT00457392
- Florence, Alabama
- Muscle Shoals, Alabama
- Scottsdale, Arizona
- Hot Springs, Arkansas
- Antioch, California
- Burbank, California
- Downey, California
- Fresno, California
- La Jolla, California
- La Jolla, California
- Montebello, California
- Pleasant Hill, California
- San Diego, California
- San Leandro, California
- Whittier, California
- Fairfield, Connecticut
- Brooksville, Florida
- Cocoa Beach, Florida
- Fort Lauderdale, Florida
- Merritt Island, Florida
- Rockledge, Florida
- Titusville, Florida
- Athens, Georgia
- Aurora, Illinois
- Goshen, Indiana
- Indianapolis, Indiana
- Council Bluffs, Iowa
- Baton Rouge, Louisiana
- Lafayette, Louisiana
- Bethesda, Maryland
- Ann Arbor, Michigan
- Troy, Michigan
- Columbus, Mississippi
- Corinth, Mississippi
- Tupelo, Mississippi
- St. Louis, Missouri
- St. Peters, Missouri
- Omaha, Nebraska
- Las Vegas, Nevada
- Las Vegas, Nevada
- Jamaica, New York
- Norman, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Tulsa, Oklahoma
- Tulsa, Oklahoma
- Tulsa, Oklahoma
- Lancaster, Pennsylvania
- Knoxville, Tennessee
- Beaumont, Texas
- Dallas, Texas
- Grapevine, Texas
- Irving, Texas
- Bountiful, Utah
- Layton, Utah
- Murray, Utah
- Provo, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Sandy, Utah
- West Valley, Utah
- Kennewick, Washington
- Buenos Aires, Capital Federal
- Ciudad Autonoma de Buenos Aires, Capital Federal
- Buenos Aires,
- Cordoba,
- Grimmenstein,
- Innsbruck,
- Linz,
- Bruxelles,
- Leuven,
- Liege,
- Rio de Janeiro, RJ
- Rio de Janeiro, RJ
- Porto Alegre, RS
- Barretos, SP
- Sao Paulo, SP
- Kingston, Ontario
- Kingston, Ontario
- Oshawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Greenfield Park, Quebec
- Levis, Quebec
- Rimouski, Quebec
- Saskatoon, Saskatchewan
- Quebec,
- Independencia, Santiago, RM
- Providencia, Santiago, RM
- Santiago,
- Medellin, Antioquia
- Medellin, Antioquia
- Ceske Budejovice,
- Nova Ves pod Plesi,
- Olomouc,
- Ostrava-Poruba,
- Praha 2,
- Praha 8,
- Pribram V,
- Tabor,
- Usti nad Labem,
- Herlev,
- Hilleroed,
- Koebenhavn OE,
- Odense,
- Bad Berka,
- Berlin,
- Dresden,
- Ebensfeld,
- Essen,
- Gauting,
- Grosshansdorf,
- Halle (Saale),
- Heidelberg,
- Homburg,
- Mainz,
- Tuebingen,
- Wiesbaden,
- Heraklion, Crete
- Alexandroupoli,
- Athens,
- Kifisia, Athens,
- Kowloon,
- Shatin, NT,
- Tuen Mun,,
- Budapest,
- Deszk,
- Gyula,
- Matrahaza,
- Szekesfehervar,
- Zalaegerszeg-Pozva,
- Catania,
- Grosseto,
- Mantova,
- Milano,
- Milano,
- Monza (MI),
- Novara,
- Orbassano (TO),
- Parma,
- Roma,
- Rozzano (MI),
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Enschede, Ov
- 's-Hertogenbosch,
- Amsterdam,
- Arnhem,
- Harderwijk,
- Maastricht,
- Rotterdam,
- Rotterdam,
- Kristiansand S,
- Oslo,
- Stavanger,
- Tromso,
- Trondheim,
- Lodz,
- Opole,
- Otwock,
- Warszawa,
- Warszawa,
- Zielona Gora,
- Moscow,
- Moscow,
- St-Petersburg,
- St. Petersburg,
- Bratislava,
- Kosice,
- Kvetnica pri Poprade,
- Nitra-Zobor,
- Zilina,
- Sabadell, Barcelona
- Palma de Mallorca, Islas Baleares
- La Laguna, Santa Cruz de Tenerife
- Dos Hermanas, Sevilla
- Barcelona,
- La Coruña,
- Madrid,
- Malaga,
- Sevilla,
- Valencia,
- Genolier,
- Gwei Shan Township, Taoyuan County
- Taichung,
- Tainan,
- Pathumwan, Bangkok
- Amphoe Mueang, Chiang Mai
- Bangkok,
- Bebington, Wirral,
- Cambridge,
- Derby,
- Dundee,
- Keighley, West Yorkshire,
- London,
- London,
- Peterborough,
- Rhyl, Denbigshire,
- Sheffield,
- Southampton,
- Yeovil, Somerset,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CarcinomaTrial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
NCT00321308
- Litchfield Park, Arizona
- Sun City, Arizona
- Bentonville, Arkansas
- Fayetteville, Arkansas
- Hudson, Florida
- New Port Richey, Florida
- Mahwah, New Jersey
- Midland Park, New Jersey
- Paramus, New Jersey
- Westwood, New Jersey
- Oneida, New York
- Oswego, New York
- Syracuse, New York
- Syracuse, New York
- Sylvania, Ohio
- Seattle, Washington
- Seattle, Washington
- Grosshansdorf,
- Mannheim,
- Torino,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CarcinomaPH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
NCT00174356
- Tampa, Florida
- Park Ridge, Illinois
- Skokie, Illinois
- Louisville, Kentucky
- Louisville, Kentucky
- Houston, Texas
- Hamilton, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CarcinomaEvaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
NCT00768755
- Huntsville, Alabama
- Atlanta, Georgia
- Decatur, Georgia
- Macon, Georgia
- Marietta, Georgia
- Sandy Springs, Georgia
- Bloomington, Illinois
- Peoria, Illinois
- Hershey, Pennsylvania
- West Reading, Pennsylvania
- East Providence, Rhode Island
- East Providence, Rhode Island
- Genova,
- Lido di Camaiore (LU),
- Orbassano (TO),
- Sunto-gun, Shizuoka
- Lubin,
- Otwock,
- Pila,
- Poznan,
- Poznan,
- Prabuty,
- Warszawa,
- Bacau,
- Iasi,
- Moscow,
- Pyatigorsk,
- Saint-Petersburg,
- St.Petersburg,
- Terrassa, Barcelona
- Castellon,
- Madrid,
- Madrid,
- Palma de Mallorca,
- Sevilla,
- Basel,
- Basel,
- Bruderholz,
- Liestal,
- Taichung,
- Taichung,
- Taipei,
- Taipei,
- Dnipropetrovsk,
- Kyiv,
- Romford, Essex
- Northwood, Middlesex
- Bournemouth,
- Brighton,
- Dundee,
- Middlesex,
- Poole,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer | |||
Official Title ICMJE | A Randomized Phase II Trial Of Pemetrexed With Or Without PF-3512676 For The Treatment Of Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer After Failure Of One Prior Chemotherapy Regimen For Advanced Disease | |||
Brief Summary | To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen | |||
Detailed Description | PF-3512676 dosing was stopped 21 June 2007 when Pfizer decided to stop the administration of PF-3512676 in all trials which combined PF-3512676 with cytotoxic chemotherapy. The decision was made subsequent to DSMC recommendation to close two phase III randomized trials in non-small cell lung cancer which also combined PF-3512676 with cytotoxic chemotherapy, citing lack of efficacy concerns as the primary reason with safety issues (sepsis, thrombocytopenia) also contributing to the decision. Subjects were allowed to complete standard of care treatment and protocol follow-up. Data collection was completed on 31 January 2008. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Carcinoma, Non-Small Cell Lung | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 36 | |||
Original Enrollment ICMJE | 130 | |||
Actual Study Completion Date ICMJE | January 2008 | |||
Actual Primary Completion Date | January 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Germany, Italy, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00321308 | |||
Other Study ID Numbers ICMJE | A8501004 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |